These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 33438101)

  • 1. Prognostic Significance of Neutrophil to Lymphocyte Ratio Dynamics in Patients with Hepatocellular Carcinoma Treated with Radioembolization Using Glass Microspheres.
    Li X; Montazeri SA; Paz-Fumagalli R; Padula CA; Wang W; Mody K; Roberts LR; Patel T; Krishnan S; Toskich B
    Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2624-2634. PubMed ID: 33438101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Patients with Unresectable Hepatocellular Carcinoma Treated with Radioembolization.
    Sukato DC; Tohme S; Chalhoub D; Han K; Zajko A; Amesur N; Orons P; Marsh JW; Geller DA; Tsung A
    J Vasc Interv Radiol; 2015 Jun; 26(6):816-24.e1. PubMed ID: 25824315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of neutrophil-to-lymphocyte ratio change in patients with locally advanced non-small cell lung cancer treated with thoracic radiotherapy.
    Yin X; Chen H; Sun Y; Xiao L; Lu H; Guo W; Yang H; Zhou J; Fan K; Liang W
    Sci Rep; 2024 May; 14(1):11984. PubMed ID: 38796631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammatory Scores: Correlation with Clinical Outcomes in Hepatocellular Carcinoma Patients Undergoing Transarterial Radioembolization.
    Young S; Rubin N; D'Souza D; Sharma P; Pontolillo J; Flanagan S; Golzarian J; Sanghvi T
    Cardiovasc Intervent Radiol; 2022 Apr; 45(4):461-475. PubMed ID: 35178599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Prognostic Role of a Combined Fibrinogen and Neutrophil-to-Lymphocyte Ratio Score in Patients with Resectable Hepatocellular Carcinoma: A Retrospective Study.
    Kong W; Xu H; Cheng J; Fang Z; Wang H; Zhang J; Wang X; Dai T; Gao Y
    Med Sci Monit; 2020 Jan; 26():e918824. PubMed ID: 31929496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy, safety, and predictors of outcomes of transarterial radioembolization for hepatocellular carcinoma: a retrospective study.
    Abdallah MA; Wongjarupong N; Hassan MA; Taha W; Abdalla A; Bampoh S; Onyirioha K; Nelson M; Glubranson LA; Wiseman GA; Fleming CJ; Andrews JC; Mahipal A; Roberts LR
    Expert Rev Gastroenterol Hepatol; 2020 Jul; 14(7):619-629. PubMed ID: 32490691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resin Versus Glass Microspheres for
    Van Der Gucht A; Jreige M; Denys A; Blanc-Durand P; Boubaker A; Pomoni A; Mitsakis P; Silva-Monteiro M; Gnesin S; Lalonde MN; Duran R; Prior JO; Schaefer N
    J Nucl Med; 2017 Aug; 58(8):1334-1340. PubMed ID: 28082436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing neutrophil-to-lymphocyte ratio following radiation is a poor prognostic factor and directly correlates with splenic radiation dose in pancreatic cancer.
    Wolfe AR; Siedow M; Nalin A; DiCostanzo D; Miller ED; Diaz DA; Arnett A; Cloyd JM; Dillhoff M; Ejaz A; Tsung A; Williams TM
    Radiother Oncol; 2021 May; 158():207-214. PubMed ID: 33667588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using Pre-Treatment Neutrophil-to-Lymphocyte Ratio to Predict the Prognosis of Young Patients with Hepatocellular Carcinoma Implemented Minimally Invasive Treatment.
    Sun S; Wang X; Chen J
    J Adolesc Young Adult Oncol; 2020 Feb; 9(1):85-89. PubMed ID: 31621472
    [No Abstract]   [Full Text] [Related]  

  • 10. Survival benefit of radioembolization for inoperable hepatocellular carcinoma using yttrium-90 microspheres.
    Kwok PC; Leung KC; Cheung MT; Lam TW; Szeto LT; Chou SQ; Chia NH; Tong CM; Yuen PK; Cheung CH; Law CK
    J Gastroenterol Hepatol; 2014 Nov; 29(11):1897-904. PubMed ID: 24734957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts Survival and Liver Toxicity in Patients With Hepatocellular Carcinoma Treated With Stereotactic Ablative Radiation Therapy.
    Lo CH; Lee HL; Hsiang CW; Chiou JF; Lee MS; Chen SW; Shen PC; Lin CS; Chang WC; Yang JF; Dai YH; Chen CY; Chia-Hsien Cheng J; Huang WY
    Int J Radiat Oncol Biol Phys; 2021 Feb; 109(2):474-484. PubMed ID: 32898609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphocytes and Neutrophil-to-Lymphocyte Ratio Variations After Selective Internal Radiation Treatment for HCC: A Retrospective Cohort Study.
    Estrade F; Lescure C; Muzellec L; Pedrono M; Palard X; Pracht M; Le Sourd S; Rolland Y; Uguen T; Garin E; Edeline J
    Cardiovasc Intervent Radiol; 2020 Aug; 43(8):1175-1181. PubMed ID: 32342156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101.
    He CB; Lin XJ
    PLoS One; 2017; 12(3):e0174769. PubMed ID: 28355305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis.
    Ozkan ZG; Poyanli A; Ucar A; Kuyumcu S; Akyuz F; Keskin S; Saglam S; Yilmaz E; Karaca C; Turkmen C
    Cancer Biother Radiopharm; 2015 Apr; 30(3):132-8. PubMed ID: 25760644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
    Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
    J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.
    Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S;
    J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival in patients with hepatocellular carcinoma treated with 90Y-microsphere radioembolization. Prediction by 18F-FDG PET.
    Sabet A; Ahmadzadehfar H; Bruhman J; Sabet A; Meyer C; Wasmuth JC; Pieper CC; Biersack HJ; Ezziddin S
    Nuklearmedizin; 2014; 53(2):39-45. PubMed ID: 24777354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Yttrium-90 Radioembolization for BCLC Stage C Hepatocellular Carcinoma Comparing Child-Pugh A Versus B7 Patients: Are the Outcomes Equivalent?
    Zu Q; Schenning RC; Jahangiri Y; Tomozawa Y; Kolbeck KJ; Kaufman JA; Al-Hakim R; Naugler WE; Nabavizadeh N; Kardosh A; Billingsley KG; Mayo SC; Orloff SL; Enestvedt KK; Maynard E; Ahn J; Lhewa D; Farsad K
    Cardiovasc Intervent Radiol; 2020 May; 43(5):721-731. PubMed ID: 32140840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio in Hepatocellular Carcinoma Treated with Stereotactic Body Radiotherapy.
    Park Y; Chang AR
    Korean J Gastroenterol; 2022 Jun; 79(6):252-259. PubMed ID: 35746839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of preoperative aspartate aminotransferase to neutrophil ratio index in patients with hepatocellular carcinoma after hepatic resection.
    Ji F; Fu S; Guo Z; Pang H; Chen D; Wang X; Ju W; Wang D; He X; Hua Y; Peng B
    Oncotarget; 2016 Nov; 7(44):72276-72289. PubMed ID: 27472390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.